SEOM clinical guidelines for the treatment of invasive bladder cancer

Clinical and Translational Oncology

Volumn 13, Issue 8, 2011, Pages 552-559

  Morales, Rafael ^a   Font, Albert ^b   Carles, Joan ^a   Isla, Dolores ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Clinical practice guidelines; Follow up; Muscle invasive bladder cancer; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PLATINUM COMPLEX; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ALOPECIA; ARTICLE; BLADDER CANCER; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION TEST; LYMPH NODE DISSECTION; METASTASIS; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER TUMOR; FEMALE; MALE; MEDICAL SOCIETY; METHODOLOGY; MUSCLE; ONCOLOGY; PATHOLOGY; RADIOTHERAPY; RECURRENT DISEASE;

CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MUSCLES; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOTHERAPY; RECURRENCE; SOCIETIES, MEDICAL; URINARY BLADDER NEOPLASMS;

EID: 84855403737     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0696-8     Document Type: Article

References (47)

1. Ferlay J, Parkin DM, Steliarova-Foucher E et al (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
2. http://www.msps.es/ciudadanos/enfLesiones/enf-NoTransmisibles/docs/ situacionCancer.pdf (Accessed Nov 2010)
3. Kaufman DS, Shipley WU, Feldman AS et al (2009) Bladder cancer. Lancet 374:239-249
4. Chalasani V, Chin JL, Izawa JI et al (2009) Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 3[6 Suppl 4]:S193-198
5. Svatek RS, Siefker-Radtke A, Dinney CP et al (2009) Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J 3[6 Suppl 4]:S228-231
6. Edge SB, Byrd DR, Compton CC et al (2010) Urinary bladder. In: AJCC Cancer Staging Manual, 7th edn. Springer, New York, p 497-502
7. Mallampati GK, Siegelman ES (2004) MR imaging of the bladder. Magn Reson Imaging Clin N Am 12:545-555 (Pubitemid 38980041)
8. Kim JK, Park SY, Ahn HJ et al (2004) Bladder cancer: analysis of multi-detector row helical CT enhancenment pattern and accuracy in tumor detection and perivesical staging. Radiology 231: 725-731 (Pubitemid 38668089)
9. Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of 18F Fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314-4320
10. Apolo AB, Riches J, Schoder H et al (2010) Clinical value of fluorine-18 2-fluoro-2-deoxy-Dglucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 28: 3973-3978
11. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666-675 (Pubitemid 32120143)
12. Karl A, Carroll PR, Gschwend JE et al (2009) The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55:826-835
13. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866 (Pubitemid 37025405)
14. Herr HW, Faulkner JR, Grossman HB et al (2004) Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22:2781-2789 (Pubitemid 41079895)
15. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533-540
16. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927-1934
17. Winquist E, Kirchner TS, Segal R et al (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171:561-569 (Pubitemid 38090430)
18. Vale CA, Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189-201
19. Paz-Ares LG, Solsona E, Esteban E et al (2010) Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Proc Am Soc Clin Oncol 28[346s]:abstr 4518
20. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
21. Nogué-Aliguer M, Carles J, Arrivi A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97:2180-2186 (Pubitemid 36444058)
22. de Wit R (2003) Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97:2120-2126 (Pubitemid 36397253)
23. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407 (Pubitemid 15129797)
24. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066-1073
25. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055 (Pubitemid 20200193)
26. Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-doseintensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638-2646 (Pubitemid 32441368)
27. Agarwal N, Hussain M (2009) Management of bladder cancer: current and emerging strategies. Drugs 69:1173-1187
28. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608 (Pubitemid 46224062)
29. Bellmunt J, von der Maase H, Mead GM et al (2007) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC30987/Intergroup Study. Proc Am Soc Clin Oncol 25[18S]: LBA5030
30. De Santis M, Bellmunt J, Mead G et al (2010) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase III results of EORTC study 30986. Proc Am Soc Clin Oncol 28[18S]:LBA4519
31. Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181 (Pubitemid 29470648)
32. Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861-870
33. Bellmunt J, Théodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4456
34. Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinumcontaining regimens. J Clin Oncol 28:1850-1855
35. Rödel C, Weiss C, Sauer R et al (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536-5544 (Pubitemid 46631334)
36. Solsona E, Iborra I, Ricós JV et al (1992) Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study. J Urol 147:1513-1515
37. Herr HW (1987) Conservative management of muscle infiltrating bladder cancer: prospective experience. J Urol 138:1162-1163 (Pubitemid 17157536)
38. Solsona E, Iborra I, Collado A et al (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184:475-480
39. Munro NP, Sundaram SK, Weston PM et al (2010) A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 77:119-124
40. Jahnson S, Damm O, Hellsten S et al (2009) A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol 43:271-276
41. Rödel C, Grabenbauer GG, Kühn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061-3071 (Pubitemid 34791095)
42. Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576-3583 (Pubitemid 28506771)
43. Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665-672 (Pubitemid 37194292)
44. Coppin CM, Gospodarowicz MK, James K et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901-2907 (Pubitemid 26371447)
45. James ND, Hussain E, Hall P et al (2010) Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 28[15s]:abstr 4517
46. Hoskin P, Rojas A, Bentzen S et al (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder cancer. J Clin Oncol (Epub ahead of print)
47. Cagiannos I, Morash C (2009) Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J 3[Suppl 4]:S237-242